{"id":63834,"date":"2026-04-23T22:08:08","date_gmt":"2026-04-23T14:08:08","guid":{"rendered":"https:\/\/flcube.com\/?p=63834"},"modified":"2026-04-23T22:08:10","modified_gmt":"2026-04-23T14:08:10","slug":"fda-expands-sanofis-tzield-approval-to-children-as-young-as-one-year-old-for-type-1-diabetes-prevention","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63834","title":{"rendered":"FDA Expands Sanofi&#8217;s Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention"},"content":{"rendered":"\n<p>The <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved a <strong>supplemental biologics license application<\/strong> for <strong>Sanofi (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>)<\/strong>&#8216;s <strong>Tzield (teplizumab-mzwv)<\/strong>, significantly expanding the indication from patients <strong>eight years and older<\/strong> to <strong>as young as one year of age<\/strong> for delaying the onset of <strong>stage 3 type 1 diabetes (T1D)<\/strong> in patients diagnosed with <strong>stage 2 T1D<\/strong>. The approval was granted under <strong>priority review<\/strong> and is supported by one-year data from the <strong>PETITE-T1D phase 4 study<\/strong> (NCT05757713) evaluating safety and pharmacokinetics in young children.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-approval-summary\">Regulatory Approval Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>FDA (United States)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Sanofi (NASDAQ: SNY)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Tzield (teplizumab-mzwv)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Supplemental biologics license application<\/td><\/tr><tr><td><strong>Review Designation<\/strong><\/td><td>Priority review<\/td><\/tr><tr><td><strong>Previous Indication<\/strong><\/td><td>Patients \u22658 years old with stage 2 T1D<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Patients \u22651 year old with stage 2 T1D<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>April 22, 2026<\/td><\/tr><tr><td><strong>Supporting Study<\/strong><\/td><td>PETITE-T1D phase 4 (NCT05757713)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-clinical-development\">Product Profile &amp; Clinical Development<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action:<\/strong> <strong>CD3-directed monoclonal antibody<\/strong> that modulates T-cell activity to preserve pancreatic beta-cell function<\/li>\n\n\n\n<li><strong>Original Approval:<\/strong> First approved in <strong>November 2022<\/strong> for patients eight years and older with stage 2 T1D<\/li>\n\n\n\n<li><strong>Clinical Significance:<\/strong> First and only therapy approved to delay progression from stage 2 to stage 3 T1D<\/li>\n\n\n\n<li><strong>New Data Source:<\/strong> <strong>PETITE-T1D phase 4 study<\/strong> provided one-year safety and pharmacokinetic data in children aged 1\u20137 years<\/li>\n\n\n\n<li><strong>Treatment Paradigm:<\/strong> Single 14-day course administered intravenously to delay clinical onset of symptomatic T1D<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Addresses critical window for intervention in very young children at high risk of developing full-blown T1D<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-assessment\">Market Impact Assessment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Expanded Patient Population<\/strong><\/td><td>Increases addressable U.S. market by approximately 60%, adding ~8,000\u201310,000 children aged 1\u20137 annually<\/td><\/tr><tr><td><strong>Market Opportunity<\/strong><\/td><td>Potential peak annual sales increase from $450 million to $700+ million by 2029<\/td><\/tr><tr><td><strong>Competitive Position<\/strong><\/td><td>Maintains exclusive position as only approved T1D-delaying therapy; no direct competitors in development<\/td><\/tr><tr><td><strong>Pricing Strategy<\/strong><\/td><td>Expected to maintain current pricing (~$100,000 per course) given significant clinical benefit and orphan drug status<\/td><\/tr><tr><td><strong>Reimbursement Outlook<\/strong><\/td><td>Favorable coverage expected given preventive nature and substantial healthcare cost savings from delayed T1D onset<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p>This expanded approval represents a transformative milestone for Sanofi&#8217;s immunology franchise and significantly enhances Tzield&#8217;s commercial potential. By extending the indication to children as young as one year old, Sanofi has effectively doubled the window for therapeutic intervention in the natural history of type 1 diabetes.<\/p>\n\n\n\n<p>The <strong>priority review designation<\/strong> and rapid approval timeline reflect the FDA&#8217;s recognition of Tzield&#8217;s substantial clinical benefit and the urgent unmet need in pediatric T1D prevention. The supporting <strong>PETITE-T1D phase 4 data<\/strong> demonstrates Sanofi&#8217;s commitment to generating robust evidence across the full pediatric age spectrum.<\/p>\n\n\n\n<p>For families affected by T1D, this approval provides hope for significantly delaying or potentially preventing the onset of a lifelong chronic condition. The ability to intervene in children as young as one year old\u2014often before any symptoms appear\u2014represents a paradigm shift in T1D management.<\/p>\n\n\n\n<p>From a commercial perspective, this expansion strengthens Sanofi&#8217;s position in the growing immunology market and provides additional growth momentum for a product that has already demonstrated strong early adoption since its 2022 launch. The company will likely accelerate physician education and screening initiatives to identify eligible young patients in the expanded age range.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding market opportunities, regulatory developments, and commercial expectations. Actual results may differ due to adoption rates, competitive dynamics, and evolving treatment guidelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63835,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,867,15,147],"class_list":["post-63834","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-diabetes","tag-nasdaq-sny","tag-product-approvals","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Expands Sanofi&#039;s Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application for Sanofi (NASDAQ: SNY)&#039;s Tzield (teplizumab-mzwv), significantly expanding the indication from patients eight years and older to as young as one year of age for delaying the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. The approval was granted under priority review and is supported by one-year data from the PETITE-T1D phase 4 study (NCT05757713) evaluating safety and pharmacokinetics in young children.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63834\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Expands Sanofi&#039;s Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention\" \/>\n<meta property=\"og:description\" content=\"The U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application for Sanofi (NASDAQ: SNY)&#039;s Tzield (teplizumab-mzwv), significantly expanding the indication from patients eight years and older to as young as one year of age for delaying the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. The approval was granted under priority review and is supported by one-year data from the PETITE-T1D phase 4 study (NCT05757713) evaluating safety and pharmacokinetics in young children.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63834\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T14:08:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-23T14:08:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2306.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63834#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63834\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Expands Sanofi&#8217;s Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention\",\"datePublished\":\"2026-04-23T14:08:08+00:00\",\"dateModified\":\"2026-04-23T14:08:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63834\"},\"wordCount\":573,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63834#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2306.webp\",\"keywords\":[\"Diabetes\",\"NASDAQ: SNY\",\"Product approvals\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63834#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63834\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63834\",\"name\":\"FDA Expands Sanofi's Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63834#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63834#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2306.webp\",\"datePublished\":\"2026-04-23T14:08:08+00:00\",\"dateModified\":\"2026-04-23T14:08:10+00:00\",\"description\":\"The U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application for Sanofi (NASDAQ: SNY)'s Tzield (teplizumab-mzwv), significantly expanding the indication from patients eight years and older to as young as one year of age for delaying the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. The approval was granted under priority review and is supported by one-year data from the PETITE-T1D phase 4 study (NCT05757713) evaluating safety and pharmacokinetics in young children.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63834#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63834\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63834#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2306.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2306.webp\",\"width\":1080,\"height\":608,\"caption\":\"FDA Expands Sanofi's Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63834#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Expands Sanofi&#8217;s Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Expands Sanofi's Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention - Insight, China&#039;s Pharmaceutical Industry","description":"The U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application for Sanofi (NASDAQ: SNY)'s Tzield (teplizumab-mzwv), significantly expanding the indication from patients eight years and older to as young as one year of age for delaying the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. The approval was granted under priority review and is supported by one-year data from the PETITE-T1D phase 4 study (NCT05757713) evaluating safety and pharmacokinetics in young children.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63834","og_locale":"en_US","og_type":"article","og_title":"FDA Expands Sanofi's Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention","og_description":"The U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application for Sanofi (NASDAQ: SNY)'s Tzield (teplizumab-mzwv), significantly expanding the indication from patients eight years and older to as young as one year of age for delaying the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. The approval was granted under priority review and is supported by one-year data from the PETITE-T1D phase 4 study (NCT05757713) evaluating safety and pharmacokinetics in young children.","og_url":"https:\/\/flcube.com\/?p=63834","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-23T14:08:08+00:00","article_modified_time":"2026-04-23T14:08:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2306.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63834#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63834"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Expands Sanofi&#8217;s Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention","datePublished":"2026-04-23T14:08:08+00:00","dateModified":"2026-04-23T14:08:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63834"},"wordCount":573,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63834#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2306.webp","keywords":["Diabetes","NASDAQ: SNY","Product approvals","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63834#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63834","url":"https:\/\/flcube.com\/?p=63834","name":"FDA Expands Sanofi's Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63834#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63834#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2306.webp","datePublished":"2026-04-23T14:08:08+00:00","dateModified":"2026-04-23T14:08:10+00:00","description":"The U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application for Sanofi (NASDAQ: SNY)'s Tzield (teplizumab-mzwv), significantly expanding the indication from patients eight years and older to as young as one year of age for delaying the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. The approval was granted under priority review and is supported by one-year data from the PETITE-T1D phase 4 study (NCT05757713) evaluating safety and pharmacokinetics in young children.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63834#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63834"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63834#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2306.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2306.webp","width":1080,"height":608,"caption":"FDA Expands Sanofi's Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63834#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Expands Sanofi&#8217;s Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2306.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63834"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63834\/revisions"}],"predecessor-version":[{"id":63836,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63834\/revisions\/63836"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63835"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}